News headlines about Intellia Therapeutics (NASDAQ:NTLA) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intellia Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8082282516804 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
- Intellia Therapeutics Inc (NTLA) Expected to Post Earnings of -$0.56 Per Share (americanbankingnews.com)
- Stocks To Watch: Intellia Therapeutics Sees RS Rating Jump To 81 (investors.com)
- Time Out: Talking Strategy For CRISPR’s Big 3 (seekingalpha.com)
- Oops! CRISPR Concerns Turn Out to be a Big Nothingburger (finance.yahoo.com)
- Intellia Therapeutics, Inc. (NTLA) – 52-Week New High Stock to Track (thestocksnews.com)
NTLA has been the subject of several research analyst reports. BidaskClub downgraded shares of Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 21st. Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, December 12th. TheStreet downgraded shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Thursday, December 14th. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, March 15th. Finally, Leerink Swann reissued an “outperform” rating on shares of Intellia Therapeutics in a research report on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Intellia Therapeutics has an average rating of “Buy” and an average target price of $34.83.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 31.27%. The business had revenue of $6.70 million for the quarter, compared to the consensus estimate of $8.84 million. During the same period in the prior year, the company earned ($0.31) EPS. Intellia Therapeutics’s quarterly revenue was up 19.6% on a year-over-year basis. equities research analysts forecast that Intellia Therapeutics will post -2.27 earnings per share for the current fiscal year.
In related news, Director Jean Francois Formela sold 39,245 shares of the business’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The disclosure for this sale can be found here. 12.80% of the stock is owned by corporate insiders.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.